These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36862518)

  • 1. Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants.
    Changrob S; Halfmann PJ; Liu H; Torres JL; McGrath JJC; Ozorowski G; Li L; Wilbanks GD; Kuroda M; Maemura T; Huang M; Zheng NY; Turner HL; Erickson SA; Fu Y; Yasuhara A; Singh G; Monahan B; Mauldin J; Srivastava K; Simon V; Krammer F; Sather DN; Ward AB; Wilson IA; Kawaoka Y; Wilson PC
    J Clin Invest; 2023 Apr; 133(8):. PubMed ID: 36862518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
    Richardson SI; Mzindle N; Motlou T; Manamela NP; van der Mescht MA; Lambson BE; Everatt J; Amoako DG; Balla S; von Gottberg A; Wolter N; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; Abdullah F; Rossouw TM; Boswell MT; Ueckermann V; Bhiman JN; Moore PL
    J Virol; 2024 Jul; 98(7):e0067824. PubMed ID: 38953380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.
    Essink BJ; Shapiro C; Isidro MGD; Bradley P; Pragalos A; Bloch M; Santiaguel J; Frias MV; Miyakis S; Alves de Mesquita M; Berrè S; Servais C; Waugh N; Hoffmann C; Baba E; Schönborn-Kellenberger O; Wolz OO; Koch SD; Ganyani T; Boutet P; Mann P; Mueller SO; Ramanathan R; Gaudinski MR; Vanhoutte N
    Hum Vaccin Immunother; 2024 Dec; 20(1):2408863. PubMed ID: 39422261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An antibody from single human V
    Luo S; Zhang J; Kreutzberger AJB; Eaton A; Edwards RJ; Jing C; Dai HQ; Sempowski GD; Cronin K; Parks R; Ye AY; Mansouri K; Barr M; Pishesha N; Williams AC; Vieira Francisco L; Saminathan A; Peng H; Batra H; Bellusci L; Khurana S; Alam SM; Montefiori DC; Saunders KO; Tian M; Ploegh H; Kirchhausen T; Chen B; Haynes BF; Alt FW
    Sci Immunol; 2022 Oct; 7(76):eadd5446. PubMed ID: 35951767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2.
    Huang KA; Chen X; Mohapatra A; Nguyen HTV; Schimanski L; Tan TK; Rijal P; Vester SK; Hills RA; Howarth M; Keeffe JR; Cohen AA; Kakutani LM; Wu YM; Shahed-Al-Mahmud M; Chou YC; Bjorkman PJ; Townsend AR; Ma C
    Nat Commun; 2023 Jan; 14(1):311. PubMed ID: 36658148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.
    Duc Dang A; Dinh Vu T; Hai Vu H; Thanh Ta V; Thi Van Pham A; Thi Ngoc Dang M; Van Le B; Huu Duong T; Van Nguyen D; Lawpoolsri S; Chinwangso P; McLellan JS; Hsieh CL; Garcia-Sastre A; Palese P; Sun W; Martinez JL; Gonzalez-Dominguez I; Slamanig S; Manuel Carreño J; Tcheou J; Krammer F; Raskin A; Minh Vu H; Cong Tran T; Mai Nguyen H; Mercer LD; Raghunandan R; Lal M; White JA; Hjorth R; Innis BL; Scharf R
    Vaccine; 2022 Jun; 40(26):3621-3632. PubMed ID: 35577631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ancestral SARS-CoV-2-Driven Antibody Repertoire Diversity in an Unvaccinated Individual Correlates with Expanded Neutralization Breadth.
    Deshpande S; Ansari MY; Sutar J; Das P; Hingankar N; Mukherjee S; Jayal P; Singh S; Anantharaj A; Singh J; Chattopadhyay S; Raghavan S; Gosain M; Chauhan S; Shrivas S; Prasad C; Chauhan S; Sharma N; Jana P; Thiruvengadam R; Kshetrapal P; Wadhwa N; Das B; Batra G; Medigeshi G; Sok D; Bhatnagar S; Garg PK; Bhattacharya J
    Microbiol Spectr; 2023 Mar; 11(2):e0433222. PubMed ID: 36946746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice.
    Zhu J; Wang Z; Li Y; Zhang Z; Ren S; Wang J; Xie S; Liao Z; Song B; Wu W; Yan F; Peng C
    J Virol; 2024 Jul; 98(7):e0052124. PubMed ID: 38874361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine.
    Feng Y; Yuan M; Powers JM; Hu M; Munt JE; Arunachalam PS; Leist SR; Bellusci L; Kim J; Sprouse KR; Adams LE; Sundaramurthy S; Zhu X; Shirreff LM; Mallory ML; Scobey TD; Moreno A; O'Hagan DT; Kleanthous H; Villinger FJ; Veesler D; King NP; Suthar MS; Khurana S; Baric RS; Wilson IA; Pulendran B
    Sci Transl Med; 2023 May; 15(695):eadg7404. PubMed ID: 37163615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profiling serum immunodominance following SARS-CoV-2 primary and breakthrough infection reveals distinct variant-specific epitope usage and immune imprinting.
    Seow J; Jefferson GCE; Keegan MD; Yau Y; Snell LB; Doores KJ
    PLoS Pathog; 2024 Nov; 20(11):e1012724. PubMed ID: 39556615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanded immune imprinting and neutralization spectrum by hybrid immunization following breakthrough infections with SARS-CoV-2 variants after three-dose vaccination.
    Jia T; Wang F; Chen Y; Liao G; Xu Q; Chen J; Wu J; Li N; Wang L; Yuan L; Wang D; Xie Q; Luo C; Luo H; Wang Y; Chen Y; Shu Y
    J Infect; 2024 Dec; 89(6):106362. PubMed ID: 39608577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omicron breakthrough infections in vaccinated or previously infected hamsters.
    Zhou J; Sukhova K; Peacock TP; McKay PF; Brown JC; Frise R; Baillon L; Moshe M; Kugathasan R; Shattock RJ; Barclay WS
    Proc Natl Acad Sci U S A; 2023 Nov; 120(45):e2308655120. PubMed ID: 37903249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.
    Meng B; Abdullahi A; Ferreira IATM; Goonawardane N; Saito A; Kimura I; Yamasoba D; Gerber PP; Fatihi S; Rathore S; Zepeda SK; Papa G; Kemp SA; Ikeda T; Toyoda M; Tan TS; Kuramochi J; Mitsunaga S; Ueno T; Shirakawa K; Takaori-Kondo A; Brevini T; Mallery DL; Charles OJ; ; ; ; Bowen JE; Joshi A; Walls AC; Jackson L; Martin D; Smith KGC; Bradley J; Briggs JAG; Choi J; Madissoon E; Meyer KB; Mlcochova P; Ceron-Gutierrez L; Doffinger R; Teichmann SA; Fisher AJ; Pizzuto MS; de Marco A; Corti D; Hosmillo M; Lee JH; James LC; Thukral L; Veesler D; Sigal A; Sampaziotis F; Goodfellow IG; Matheson NJ; Sato K; Gupta RK
    Nature; 2022 Mar; 603(7902):706-714. PubMed ID: 35104837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotyping the virulence of SARS-CoV-2 variants in hamsters by digital pathology and machine learning.
    Meehan GR; Herder V; Allan J; Huang X; Kerr K; Mendonca DC; Ilia G; Wright DW; Nomikou K; Gu Q; Molina Arias S; Hansmann F; Hardas A; Attipa C; De Lorenzo G; Cowton V; Upfold N; Palmalux N; Brown JC; Barclay WS; Filipe ADS; Furnon W; Patel AH; Palmarini M
    PLoS Pathog; 2023 Nov; 19(11):e1011589. PubMed ID: 37934791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep mutational scans for ACE2 binding, RBD expression, and antibody escape in the SARS-CoV-2 Omicron BA.1 and BA.2 receptor-binding domains.
    Starr TN; Greaney AJ; Stewart CM; Walls AC; Hannon WW; Veesler D; Bloom JD
    PLoS Pathog; 2022 Nov; 18(11):e1010951. PubMed ID: 36399443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-sectional and longitudinal genotype to phenotype surveillance of SARS-CoV-2 variants over the first four years of the COVID-19 pandemic.
    Akerman A; Fichter C; Milogiannakis V; Esneau C; Silva MR; Ison T; Lopez JA; Naing Z; Caguicla J; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Boss T; Condylios A; Yeang M; Sato K; Bartlett NN; Darley D; Matthews G; Stark DJ; Promsri S; Rawlinson WD; Murrell B; Kelleher AD; Dwyer D; Sintchenko V; Kok J; Ellis S; Marris K; Knight E; Hoad VC; Irving DO; Gosbell I; Brilot F; Wood J; Aggarwal A; Turville SG
    EBioMedicine; 2024 Dec; 110():105415. PubMed ID: 39549677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial.
    Goswami J; Cardona JF; Hsu DC; Simorellis AK; Wilson L; Dhar R; Tomassini JE; Wang X; Kapoor A; Collins A; Righi V; Lan L; Du J; Zhou H; Stoszek SK; Shaw CA; Reuter C; Wilson E; Miller JM; Das R;
    Lancet Infect Dis; 2024 Nov; ():. PubMed ID: 39608389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study.
    van Gils MJ; Lavell A; van der Straten K; Appelman B; Bontjer I; Poniman M; Burger JA; Oomen M; Bouhuijs JH; van Vught LA; Slim MA; Schinkel M; Wynberg E; van Willigen HDG; Grobben M; Tejjani K; van Rijswijk J; Snitselaar JL; Caniels TG; ; Vlaar APJ; Prins M; de Jong MD; de Bree GJ; Sikkens JJ; Bomers MK; Sanders RW
    PLoS Med; 2022 May; 19(5):e1003991. PubMed ID: 35580156
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.